New frontiers in the therapy of tuberculosis: Fighting with the global menace

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 401-430

  Chhabria, Mahesh ^a   Jani, Mitesh ^b   Patel, Shailesh ^a  

^a L M COLLEGE OF PHARMACY   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antituberculous drugs; Mycobacterium tuberculosis; Novel targets; Resistance

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; AMIKACIN; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CLOSANTEL; CYCLOSERINE; DIHYDROFOLATE REDUCTASE INHIBITOR; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; MYCOLIC ACID; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PENICILLIN G; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; THIOACETAZONE; THIOLACTOMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; FATTY ACID SYNTHESIS; GENE IDENTIFICATION; GENE SEQUENCE; GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; KNOCKOUT GENE; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA SYNTHESIS; SHORT COURSE THERAPY; STRUCTURE ACTIVITY RELATION; TRANSPOSON; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; BACTERIAL GENOME; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENOME, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 67549129472     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787847949     Document Type: Review

References (318)

1. World Health Organization. 2008. Global tuberculosis Control: surveillance, planning, financing. WHO Report, Geneva, Switzerland. (WHO/ HTM/TB/2008.393). http://www.who.int/tb/publications/2008/ factsheet_april08.pdf
2. Frieden, T.R.; Sterling, T.R.; Munsiff, S.S.; Watt, C.J.; Dye, C. Tuberculosis. Lancet, 2003, 362, 887-99.
3. Shah, N.S.; Wright, A.; Drobniewski, F. Extreme drug resistance in tuberculosis ("XDR-TB"): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int. J. Tuberc. Lung Dis., 2005, 9(Suppl 1), S77.
4. Holtz, T.H.; Riekstina, V.; Zarovska, E.; Laserson, K.F.; Wells, C.D.; Leimane, V. XDR-TB: extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000-2002. Int. J. Tuberc. Lung Dis., 2005, 9(Suppl 1), S258.
5. O'Brien, R.J.; Nunn, P.P. The need for new drugs against tuberculosis obstacles, opportunities, and next steps. Am. J. Respir. Crit. Care Med., 2001, 163, 1055-58.
6. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E., 3rd; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-44.
7. Chung, G.A.; Aktar, Z.; Jackson, S.; Duncan, K. High-throughput screen for detecting antimycobacterial agents. Antimicrob. Agents Chemother., 1995, 39, 2235-38.
8. Orme, I. Search for new drugs for treatment of tuberculosis. Antimicrob. Agents Chemother., 2001, 45, 1943-46.
9. Kayukova, L.A.; Praliev, K.D. Main directions in the search for new antituberculous drugs. Pharm. Chem. J., 2000, 34, 11-18.
10. Newton, S.M.; Lau, C.; Wright, C.W. A review of antimycobacterial natural products. Phytother. Res., 2002, 14, 303-22.
11. Copp, B. R. Antimycobacterial natural products. Nat. Prod. Rep., 2003, 20, 535-57.
12. Okunade, A.L.; Elwin-Lewis, M.P.F.; Lewis, W.H. Natural antimycobacterial metabolites: current status. Phytochemistry, 2004, 65, 1017-32.
13. Sharma, K.; Chopra, P.; Singh, Y. Recent advances towards identification of new drug targets for Mycobacterium tuberculosis. Expert Opin. Ther. Targets, 2004, 8, 79-93.
14. Ballell, L.; Field, R.A.; Duncan, K.; Young, R.J. New small molecule synthetic antimycobacterials. Antimicrob. Agents Chemother., 2005, 49, 2153-63.
15. Zhang, Y.; Amzel, L.M. Tuberculosis drug targets. Curr. Drug Targets, 2002, 3, 131-54.
16. Duncan, K.; Sacchettini, J.C. In Molecular Genetics of Mycobacteria; Hatfull G.F.; Jacobs, W.R., Jr., Eds.; ASM Press: Washington DC; 2000; 297-307.
17. Smith, C.V.; Sacchettini, J.C. Mycobacterium tuberculosis: a model system for structural genomics. Curr. Opin. Struct. Biol., 2003, 13, 658-64.
18. Duncan, K. Identification and validation of novel drug targets in tuberculosis. Curr. Pharm. Des., 2004, 10, 3185-94.
19. Zhang, Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 529-64.
20. Nayyar, A.; Jain, R. Recent advances in new structural classes of anti-tuberculosis agents. Curr. Med. Chem., 2005, 12, 1873-1886.
21. Mdluli, K.; Spigelman, M. Novel targets for tuberculosis drug discovery. Curr. Opin. Pharmacol., 2006, 6, 459-67.
22. Vohra, R.; Gupta, M.; Chaturvedi, R.; Singh, Y. Attack on the scourge of tuberculosis: patented drug targets. Recent Pat. Anti-Infect. Drug Discov., 2006, 1, 95-106.
23. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des., 2006, 12, 4047-70.
24. Liu, J.; Ren, H.P. Tuberculosis: Current treatment and new drug development. Anti-Infective Agents Med. Chem., 2006, 5, 331-44.
25. Janin, Y.L. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem., 2007, 15, 2479-13.
26. Porrero, J.L., Rubio, M. New antituberculosis therapies. Expert Opin. Ther. Pat., 2007, 17, 617-37.
27. Dormandy, T. The White Death: A History of Tuberculosis. Hambledon Press: London, 1999.
28. Schatz, A.; Waksman, S.A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc. Soc. Exp. Biol. Med., 1944, 57, 244-48.
29. Lehman, J. Determination of pathogenicity of tubercule bacilli by their intermediate metabolism. Lancet, 1946, 250, 15-20.
30. Crofton, J.; Mitchison, D.A. Streptomycin resistance in pulmonary tuberculosis. Br. Med. J., 1948, 2, 1009-15.
31. Vynnycky, E.; Fine, P.E. The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901. Int. J. Tuberc. Lung Dis., 1997, 1, 389-96.
32. Snider, D.E., Jr.; La Montagne; J.R. The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis. J. Infect. Dis., 1994, 169, 1189-96.
33. Mitchison, D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am. J. Respir. Crit. Care Med., 2005, 171, 699-706.
34. Kimerling, M.E.; Kluge, H.; Vezhnina, N.; Iacovazzi, T.; Demeulenaere, P.F. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int. J. Tuberc. Lung Dis., 1999, 3, 451-53.
35. DeCock, K.M.; Chaisson, R.E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int. J. Tuberc. Lung Dis., 1999, 3, 457-65.
36. Mukherjee, J.S.; Rich, M.L.; Socci, A.R.; Joseph, J.K.; Viru, F.A.; Shin, S.S.; Furin, J.J.; Becerra, M.C.; Barry, D.J.; Kim, J.Y.; Bayona, J.; Farmer, P.; Smith Fawzi, M.C.; Seung, K.J. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet, 2004, 363, 474-81.
37. McKinney, J.D.; Honer zu Bentrup, K.; Munoz-Elias, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R., Jr.; Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-38.
38. Pablos-Mendez, A. Working Alliance for TB Drug Development, Cape Town, South Africa, February 8th, 2000 Declaration. Int. J. Tuberc. Lung Dis., 2000, 4, 489-90.
39. Wayne, L.G. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis., 1994, 13, 908-14.
40. Elliott, A.M.; Berning, S.E.; Iseman, M.D.; Peloquin, C.A. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuberc. Lung Dis., 1995, 76, 463-67.
41. Iseman, M.D.; Madsen, L.A. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest, 1991, 100, 124-27.
42. Jidani, A.; Aber, V.; Edwards, E.A.; Mitchison, D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 1980, 121, 939-49.
43. Forget, E.J.; Menzies, D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf., 2006, 5, 231-49.
44. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase - peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992, 358, 591-93.
45. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K.S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W.R., Jr. Inh A, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 1994, 263, 227-30.
46. Mdluli, K.; Slayden, R.A.; Zhu, Y.; Ramaswamy, S.; Parnd, X.; Mead, D.; Crane, D.D.; Musser, J.M.; Barry, C.E. 3rd Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science, 1998, 280, 1607-10.
47. Heym, B.; Saint-Joanis, B.; Cole, S.T. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuberc. Lung Dis., 1999, 79, 267-71.
48. Zhang, Y.; Telenti, A.; Hatfull, G.F.; Jacobs, W.R., Jr. In Molecular Genetics of Mycobacteria, ASM Press: Eds.; Washington DC, 2000, pp. 235-54.
49. Lee, A.S.G.; Teo, A.S.M.; Wong, S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother., 2001, 45, 2157-59.
50. Gillespie, S.H. Evolution of drug resistance in mycobacterium tuberculosis: clinical and molecular perspective. Antimicro. Agents Chemother., 2002, 46, 267-74.
51. Sreevatsan, S.; Stockbauer, K.E.; Pan, X.; Kreiswirth, B.N.; Moghazeh, S.L.; Jacobs, W.R., Jr.; Telenti, A.; Musser, J.M. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother., 1997, 41, 1677-81.
52. Hirano, K.; Takahashi, M.; Kazumi, Y.; Fukasawa, Y.; Abe, C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuberc. Lung Dis., 1997, 78, 117-22.
53. Lemaitre, N.; Sougakoff, W.; Truffot-Pernot, C.; Jarlier, V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother., 1999, 43, 1761-63.
54. Musser, J.M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev., 1995, 8, 496-514.
55. Ramaswamy, S.; Musser, J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis., 1998, 79, 3-29.
56. Sreevatsan, S.; Pan, X.; Stockbauer, K.E.; Williams, D.L.; Kreiswirth, B.N.; Musser, J.M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob. Agents Chemother., 1996, 40, 1024-26.
57. Caceres, N.E.; Harris, N.B.; Wellehan, J.F.; Feng, Z.; Kapur, V.; Barlettaet, R.G. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J. Bacteriol., 1997, 179, 5046-55.
58. Feng, Z.; Barletta R.G. Roles of Mycobacterium smegmatis D-Alanine: D-Alanine ligase and D-Alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-Cycloserine. Antimicrob. Agents Chemother., 2003, 47, 283-91.
59. Rengarajan, J.; Sassetti, C.M.; Naroditskaya, V.; Sloutsky, A.; Bloom, B.R.; Rubin, E.J. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol., 2004, 53, 275-82.
60. Sun, Z.; Chao, Y.; Zhang, X.; Zhang, J.; Li, Y.; Qiu, Y.; Liu, Y.; Nie, L.; Guo, A.; Li, C. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J. Clin. Microbiol., 2008, 46, 4075-77.
61. Maus, C.E.; Plikaytis, B.B.; Shinnick, T.M. Mutation of tlyA Confers Capreomycin Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 571-77.
62. Madsen, C.T.; Jakobsen, I.; Buriankova, K.; Doucet-Populaire. F.; Pernodet, J.L.; Douthwaite, S. Methyltransferase erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis. J. Biol. Chem., 2005, 280, 38942-47.
63. Schroeder, E. K.; De Souza, O.N.; Santos, D.S.; Blanchard, J.S.; Basso, L.A. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol., 2002, 3, 197-225.
64. Yatvin, M.B.; Pederson, R.L. Anti-mycobacterial compounds. Patent WO 02 04,478; Chem. Abstr. 2002, 136, 12622n.
65. Yatvin, M.B.; Pederson, R.L. Anti-mycobacterial compounds. Patent U.S. 2004 224,918; Chem. Abstr. 2005, 141, 374701m.
66. Broussy, S.; Bernardes-Genisson, V.; Quemard, A.; Meunier, B.; Bernadou, J. The first chemical synthesis of the core structure of the benzoylhydrazine - NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase. J. Org. Chem., 2005, 70, 10502-10.
67. Broussy, S.; Bernardes-Genisson, V.; Gornitzka, H.; Bernadou, J.; Meunier, B. Studies on the 4-benzoylpyridine-3-carboxamide entity as a fragment model of the isoniazid-NAD adduct. Org. Biomol. Chem., 2005, 3, 666-69.
68. Ducasse-Cabanot, S.; Cohen-Gonsaud, M.; Marrakchi, H.; Nguyen, M.; Zerbid, D.; Bernadou, J.; Daffe', M.; Labesse, G.; Quemard, A. In vitro inhibition of the Mycobacterium tuberculosis β-ketoacylacyl carrier protein reductase MabA by isoniazid. Antimicrob. Agents Chemother., 2004, 48, 242-49.
69. Argyrou, A.; Vetting, M.W.; Aladegbami, B.; Blanchard, J.S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol., 2006, 13, 408-13.
70. Hearn, M.J. Antimycobacterial compounds and method for making the same. Patent WO 0243668; Chem. Abstr. 2002, 137, 20296b.
71. Sinha, N.; Jain, S.; Tilekar, A.; Upadhayaya, R.S.; Kishore, N.; Jana, G.H.; Arora, S.K. Synthesis of isonicotinic acid N'-arylidene-N-2-oxo-2-(4-aryl-piperazin-1-yl)-ethyl-hydrazides as antituberculosis agents. Bioorg. Med. Chem. Lett., 2005, 15, 1573-76.
72. Sriram, D.; Yogeeswari, P.; Madhu, K. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. Bioorg. Med. Chem. Lett., 2005, 15, 4502-05.
73. 1-nicotinoyl-3-(4′-hydroxy-3′-methyl phenyl)-5-(sub)phenyl-2-pyrazolines. Bioorg. Med. Chem. Lett., 2006, 16, 3947-49.
74. Velikorodov, A.V.; Urlyapva, N.G.; Daudova, A.D. Synthesis and antimycobacterial activity of triazene derivatives of N-arylcarbamates. Pharm. Chem. J., 2005, 39, 126-28.
75. Sriram, D.; Yogeeswari, P.; Madhu, K. Synthesis and in vitro antitubercular activity of some 1-(4-sub)phenyl-3-(4-{1- (pyridine-4-carbonyl)hydrazonoethyl} phenyl)thiourea. Bioorg. Med. Chem. Lett., 2006, 16, 876-78.
76. Kamal, A.; Srinivasa Reddy, K.; Kaleem Ahmed, S.; Khan, M.N.; Sinha, R.K.; Yadav, J.S.; Arora, S.K. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity. Bioorg. Med. Chem., 2006, 14, 650-58.
77. DeLogu, A.; Saddi, M.; Onnis, V.; Sanna, C.; Congiu, C.; Borgna, R.; Cocco, M.T. In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium. Int. J. Antimicrob. Agents, 2005, 26, 28-32.
78. Parker, K. J.; Rathbone, D.L.; Lambert, P.A.; Billington, D.C. Intramedullary nail. Patent WO 2006 111716, 2006.
79. Scior, T.; Garcés-Eisele, S.J. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. Curr. Med. Chem., 2006, 13, 2205-19.
80. Pasqualoto, K.F.M.; Ferreira, E.I.; Santos-Filho, O.A.; Hopfinger, A.J. Rational design of new antituberculosis agents: receptorindependent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives. J. Med. Chem., 2004, 47, 3755-64.
81. Cynamon, M.H.; Speirs, R.J.; Welch, J.T. In Vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother., 1998, 42, 462-63.
82. Speirs, R.J.; Welch, J.T.; Cynamon, M. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob. Agents Chemother., 1995, 39, 1269-71.
83. Cynamon, M.H.; Gimi, R.; Gyenes, F.; Sharpe, C. A.; Bergmann, K.E.; Han, H.J.; Gregor, L.B.; Rapolu, R.; Luciano, G.; Welch, J.T. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem., 1995, 38, 3902-07.
84. Bergmann, K.E.; Cynamon, M.H.; Welch, J.T. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J. Med. Chem., 1996, 39, 3394-400.
85. Yamamoto, S.; Toida, I.; Watanabe, N.; Ura, T. In vitro antimyco-bacterial activities of pyrazinamide analogs. Antimicrob. Agents Chemother., 1995, 39, 2088-91.
86. Wächter, G.A.; Davis, M.C.; Martin, A.R.; Franzblau, S.G. Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. J. Med. Chem. 1998, 41, 2436-38.
87. Gezginci, M.H.; Martin, A.R.; Franzblau, S.G. Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2. J. Med. Chem., 2001, 44, 1560-63.
88. Seitz, L.E.; Suling, W.J.; Reynolds, R.C. Synthesis and antimyco-bacterial activity of pyrazine and quinoxaline derivatives. J. Med. Chem., 2002, 45, 5604-06.
89. Zimhony, O.; Vilcheze, C.; Arai, M.; Welch, J.; Jacobs, W.R., Jr. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob. Agents Chemother., 2007, 51, 752-54.
90. DeBarber, A.E.; Mdluli, K.; Bosman, M.; Bekker, L.G.; Barry, C.E., 3rd Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2000, 97, 9677-82.
91. Vannelli, T.A.; Dykman, A.; Ortiz de Montellano, P.R. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem., 2002, 277, 12824-29.
92. McMurry, L.M.; Oethinger, M.; Levy, S. Triclosan targets lipid synthesis. Nature, 1998, 394, 531-32.
93. Ward, W.H.; Holdgate, G.A.; Rowsell, S.; McLean, E.G.; Pauptit, R.A.; Clayton, E.; Nichols, W.W.; Colls, J.G.; Minshull, C.A.; Jude, D.A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N.J.; Britton, C.J.; Taylor, I.W. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry, 1999, 38, 12514-25.
94. Parikh, S.L.; Xiao, G.; Tonge, P.J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry, 2000, 39, 7645-50.
95. Sivaraman, S.; Zwahlen, J.; Bell, A.F.; Hedstrom, L.; Tonge, P.J. Structure-activity studies of the inhibition of fabi, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. Biochemistry, 2003, 42, 4406-13.
96. Kuo, M.R.; Morbidoni, H.R.; Alland, D.; Sneddon, S.F.; Gourlie, B.B.; Staveski, M.M.; Leonard, M.; Gregory, J.S.; Janjigian, A.D.; Yee, C.; Musser, J.M.; Kreiswirth, B.N.; Iwamoto, H.; Perozzo, R.; Jacobs, W.R.; Sacchettini, J.C.; Fidock, D.A. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem., 2003, 278, 20851-59.
97. Perozzo, R.; Kuo, M.; Sidhu, A.S.; Valiyaveettil, J.T.; Bittman, R.; Jacobs, W.R., Jr.; Fidock, D.A.; Sacchettini, J.C. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem., 2002, 277, 13106-14.
98. Heath, R.J.; Rubin, J.R; Holland, D.R.; Zhang, E.; Snow, M.E.; Rock, C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem., 1999, 274, 11110-14.
99. Qiu, X.; Janson, C.A.; Court, R.I.; Smyth, M.G.; Payne, D.J.; Abdel-Meguid, S.S. Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci., 1999, 8, 2529-32.
100. Sivaraman, S.; Sullivan, T.J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P.J. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem., 2004, 47, 509-18.
101. Sullivan, T.J.; Truglio, J.J.; Boyne, M.E.; Novichenok, P.; Zhang, X.; Stratton, C.F.; Li, H.-J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R.A.; Kisker, C.; Tonge, P.J. High affinity inha inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol., 2006, 1, 43-53.
102. Kremer, L.; Douglas, J.D.; Baulard, A.R.; Morehouse, C.; Guy, M.R.; Alland, D.; Dover, L.G.; Lakey, J.H.; Jacobs, W.R.; Brennan, P.J.; Minnikin, D.E.; Besra, G.S. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem., 2000, 275, 16857-64.
103. Senior, S.J.; Illarionov, P.A.; Gurcha, S.S.; Campbell, I.B.; Schaeffer, M.L.; Minnikin, D.E.; Besra, G.S. Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. Bioorg. Med. Chem. Lett., 2003, 13, 3685-88.
104. McFadden, J.M.; Medghalchi, S.M.; Thupari, J.N.; Pinn, M.L.; Vadlamudi, A.; Miller, K.I.; Kuhajda, F.P.; Townsend, C.A. Application of a Flexible Synthesis of (5R)-Thiolactomycin To develop new inhibitors of type I fatty acid synthase. J. Med. Chem., 2005, 48, 946-61.
105. Kim, P.; Zhang, Y.M.; Shenoy, G.; Nguyen, Q.A.; Boshoff, H.I.; Manjunatha, U.H.; Goodwin, M.B.; Lonsdale, J.; Price, A.C.; Miller, D.J.; Duncan, K.; White, S.W.; Rock, C.O.; Barry, C.E., 3rd; Dowd, C.S. Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli. J. Med. Chem., 2006, 49, 159-71.
106. Douglas, J.D.; Senior, S.J.; Morehouse, C.; Phetsuksiri, B.; Campbell, I.B.; Besra, G.S.; Minnikin, D.E. Analogues of thiolactomycin: potential drugs with enhanced antimycobacterial activity. Microbiology, 2002, 148, 3101-09.
107. Kamal, A.; Shaik, A.A.; Sinha, R.; Yadav, J.S.; Arora, S.K. Antitubercular agents. Part 2: New thiolactomycin analogues active against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 2005, 15, 1927-29.
108. Jones, P.; Parrish, N.M.; Houston, T.A.; Stapon, A.; Bansal, N.P.; Dick, J.D.; Townsend, C.A. A New class of antituberculosis agents. J. Med. Chem., 2000, 43, 3304-14.
109. Parrish, N.M.; Houston, T.; Jones, P.B.; Townsend, C.; Dick, J.D. In vitro activity of a novel antimycobacterial compound, n-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob. Agents Chemother., 2001, 45, 1143-50.
110. Tousek, J.; Freerksen, E.; Orlowski, E.H. In Antibiotic and Chemotherapy, Thumin, H.J., Eds.; S. Karger AG: Basel, 1970, Vol. 16, pp.149-55.
111. Urbancik, B.; Freerksen, E.; Orlowski, E.H. In Antibiotic and Chemotherapy, Thumin, H.J., Eds.; S. Karger AG: Basel, 1970, Vol. 16, pp. 117-23.
112. Gallen, C.S.; Freerksen, E.; Orlowski, E.H. In Antibiotic and Chemotherapy, Thumin, H.J., Eds.; S. Karger AG: Basel, 1970, Vol. 16, pp. 139-48.
113. Phetsuksiri, B.; Jackson, M.; Scherman, H.; McNeil, M.; Besra, G.S.; Baulard, A.R.; Slayden, R.A.; DeBarber, A.E.; Barry, C.E., 3rd; Baird, M.S.; Crick, D.C.; Brennan, P.J. Lipids and lipoproteins: unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem., 2003, 278, 53123-30.
114. Azzi, A.; Casey, R.P.; Nalecz, M. The effect of N,N'-dicyclohexyl-carbodiimide on enzymes of bioenergetic relevance. Biochim. Biophys. Acta, 1984, 768, 209-26.
115. Abrams, A.; Baron, C. Inhibitory action of carbodiimides on bacterial membrane ATPase. Biochem. Biophys. Res. Commun., 1970, 41, 858-63.
116. Phetsuksiri, B.; Baulard, A.R.; Cooper, A.M.; Minnikin, D.E.; Douglas, J.D.; Besra, G.S.; Brennan, P.J. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob. Agents Chemother., 1999, 43, 1042-51.
117. Stover, C.K.; Warrener, P.; VanDevanter, D.R.; Sherman, D.R.; Arain, T.M.; Langhorne, M.H.; Anderson, S.W.; Towell, J.A.; Yuan, Y.; McMurray, D.N.; Kreiswirth, B.N.; Barry, C.E., 3rd; Baker, W.R. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-66.
118. Manjunatha, U.H.; Boshoff, H.; Dowd, C.S.; Zhang, L.; Albert, T.J.; Norton, J.E.; Daniels, L.; Dick, T.; Pang, S.S.; Barry, C.E., 3rd Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 431-36.
119. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 2006, 3, 2131-44.
120. Shepherd, R.G.; Baughn, C.; Cantrall, M.L.; Goodstein, B.; Thomas, J.P.; Wilkinson, R.G. Structure-activity studies leading to ethambutol, a new type of antituberculous compound. Ann. N.Y. Acad. Sci., 1966, 135, 686-710.
121. Bernardi, L.; Foglio, M.; Temperilli, A. Ethambutol. Synthesis of an unsaturated analog. J. Med. Chem., 1974, 17, 555-56.
122. Lee, R.E.; Protopopova, M.; Crooks, E.; Slayden, R.A.; Terrot, M.; Barry, C.E., 3rd Combinatorial lead optimization of [1,2]-Diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem., 2003, 5, 172-87.
123. Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C.A. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother., 2005, 56, 968-74.
124. Bogatcheva, E.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Barbosa, F.; Einck, L.; Nacy, C.A.; Protopopova, M. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem., 2006, 49, 3045-48.
125. Liger, D.; Masson, A.; Blanot, D.; Van Heijenoort, J.; Parquet, C. Over-production, purification and properties of the uridine-diphosphate-N -acetylmuramate: l-alanine ligase from Escherichia coli. Eur. J. Biochem., 1995, 230, 80-87.
126. Gubler, M.; Appoldt, Y.; Keck, W. Overexpression, purification, and characterization of UDP-N-acetylmuramyl:L-alanine ligase from Escherichia coli. J. Bacteriol., 1996, 178, 906-10.
127. Emanuele, J.J., Jr.; Jin, H.; Jacobson, B.L.; Chang, C.Y.; Einspahr, H.M.; Villafranca, J.J. Kinetic and crystallographic studies of Escherichia coli UDP-N-acetylmuramate:L-alanine ligase. Protein Sci., 1996, 5, 2566-74.
128. Tripathi, R.P.; Tripathi, R.; Tiwari, V.K.; Bala, L.; Sinha, S.; Srivastava, A.; Srivastava, R.; Srivastava, B.S. Synthesis of glycosylated beta-amino acids as new class of antitubercular agents. Eur. J. Med. Chem., 2002, 37, 773-81.
129. Kohn, H.; Kim, M.G.; Krause, K.L.; Briggs, J.M.; Benedik, M.J.; Strych, U. Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine. Patent WO 2005 20,973; see Chem. Abstr. 2005, 142, 291324k.
130. Moe, S.T.; Ala, P.J.; Perola, E.; Faerman, C.H.; Clement, J.J.; Ali, J.A.; Will, P.M.; Marchese, S.A.; Magee, A.S.; Gazzaniga, J.V.; Farady, C.; Navia, M.A.; Connelly, P.R. Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors. Patent WO 03 1887; see Chem. Abstr. 2003, 138, 66661r.
131. Ryll, R.; Kumazawa, Y.; Yano, I. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acidcontaining glycolipids - a review. Microbiol. Immunol., 2001, 45, 801-11.
132. Belisle, J.T.; Vissa, V.D.; Sievert, T.; Takayama, K.; Brennan, P.J.; Besra, G.S. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science, 1997, 276, 1420-22.
133. Rose, J.D.; Maddry, J.A.; Comber, R.N.; Suling, W.J.; Wilson, L.N.; Reynolds, R.C. Synthesis and biological evaluation of trehalose analogs as potential inhibitors of mycobacterial cell wall biosynthesis. Carbohydr. Res., 2002, 337, 105-20.
134. Hui, Y.; Chang, C.W.T. Convenient divergent synthesis of a library of trehalosamine analogs. Org. Lett., 2002, 4, 2245-48.
135. Wang, J.; Elchert, B.; Hui, Y.; Takemoto, J.Y.; Bensaci, M.; Wennergren, J.; Chang, H.; Rai, R.; Chang, C.W. Synthesis of trehalose-based compounds and their inhibitory activities against Mycobacterium smegmatis. Bioorg. Med. Chem., 2004, 24, 6397-413.
136. Ma, Y.; Stern, R.J.; Scherman, M.S.; Vissa, V.D.; Yan, W.; Jones, V.C.; Zhang, F.; Franzblau, S.G.; Lewis, W.H.; McNeil, M.R. Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDPglucose to dTDP-rhamnose. Antimicrob. Agents Chemother., 2001, 5, 1407-16.
137. Küçükgüzel, S.G.; Oruç, E.E.; Rollas, S.; Şahin, F.; Özbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur. J. Med. Chem., 2002, 37, 197-206.
138. Grant, E.B.; Guiadeen, D.; Baum, E.Z.; Foleno, B.D.; Jin, H.; Montenegro, D.A.; Nelson, E.A.; Bush, K.; Hlasta, D.J. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2179-82.
139. Babaoglu, K.; Page, M.A.; Jones, V.C.; McNeil, M.R.; Dong, C.; Naismith, J.H.; Lee, R.E. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg. Med. Chem. Lett., 2003, 13, 3227-30.
140. f disaccharides as substrates for mycobacterial galactosyltransferase activity. Bioorg. Med. Chem., 2001, 9, 3129-43.
141. Pathak, A.K.; Pathak, V.; Suling, W.J.; Gurcha, S.S.; Morehouse, C.B.; Besra, G.S.; Maddry, J.A.; Reynolds, R.C. Studies on n-Octyl-5-(α-D-arabinofuranosyl)- β-D-galactofuranosides for Mycobacterial Glycosyltransferase Activity. Bioorg. Med. Chem., 2002, 10, 923-28.
142. Wen, X.; Crick, D.C.; Brennan, P.J.; Hultin, P.G. Analogues of the mycobacterial arabinogalactan linkage disaccharide as cell wall biosynthesis inhibitors. Bioorg. Med. Chem., 2003, 11, 3579-87.
143. Cociorva, O.M.; Gurcha, S.S.; Besra, G.S.; Lowary, T.L. Oligosac-charides as inhibitors of mycobacterial arabinosyltransferases. Diand trisaccharides containing C-3 modified arabinofuranosyl residues. Bioorg. Med. Chem., 2005, 15, 1369-79.
144. Pathak, A.K.; Pathak, V.; Maddry, J.A.; Suling, W.J.; Gurcha, S.S.; Besra, G.S.; Reynolds, R.C. Studies on α(1→5) linked octyl arabinofuranosyl disaccharides for mycobacterial arabinosyl transferase activity. Bioorg. Med. Chem., 2001, 9, 3145-51.
145. Bosco, M.; Bisseret, P.; Constant, P.; Eustache, J. Synthesis of 2′,3′-dihydrosolanesyl analogues of β-d-arabinofuranosyl-1-monophosphoryldecaprenol with promising antimycobacterial activity. Tetrahedron Lett. 2007, 48, 153-57.
146. Owen, D.J.; Davis, C.B.; Hartnell, R.D.; Madge, P.D.; Thomson, R.J.; Chong, A.K.J.; Coppel, R.L.; von Itzstein, M. Synthesis and evaluation of galactofuranosyl N,N-dialkyl sulfenamides and sulfonamides as antimycobacterial agents. Bioorg. Med. Chem. Lett., 2007, 17, 2274-77.
147. Centrone, C.A.; Lowary, T.L. Sulfone and phosphinic acid analogs of decaprenolphosphoarabinose as potential anti-tuberculosis agents. Bioorg. Med. Chem., 2002, 12, 5495-503.
148. Centrone, C.A.; Lowary, T.L. Synthesis and antituberculosis activity of C-phosphonate analogues of decaprenolphosphoarabinose, a key intermediate in the biosynthesis of mycobacterial arabinogalactan and lipoarabinomannan. J. Org. Chem., 2002, 67, 8862-70.
149. Barry, V.C.; Belton, J.G.; Conalty, M.L.; Denneny, J.M.; Edward, D.W.; O'Sullivan, J.F.; Twomey, D.; Wnder, F. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature, 1957, 179, 1013-15.
150. Oliva, B.; O'Neill, A.J.; Miller, K.; Stubbings, W.; Chopra, I. Anti-staphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother., 2004, 53, 435-40.
151. VanRensburg, C.E.; Joone, G.K.; Sirgel, F.A.; Matlola, N.M.; O'Sullivan, J.F. In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine substituted phenazines against Mycobacterium tuberculosis. Chemotherapy, 2000, 46, 43-48.
152. Matlola, N.M.; Steel, H.C.; Anderson, R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J. Antimicrob. Chemother., 2001, 47, 199-02.
153. Reddy, V.M.; O'Sullivan, J.F.; Gangadharam, P.R.J. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother., 1999, 43, 615-23.
154. Brandish, P.E.; Kimura, K.I.; Inukai, M.; Southgate, R.; Lonsdale, J.T.; Bugg, T.D. Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Antimicrob. Agents Chemother., 1996, 40, 1640-44.
155. Muramatsu, Y.; Ishii, M.M.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G. J. Antibiot., 2003, 56, 253-58.
156. Muramatsu, Y.; Miyakoshi, S.; Ogawa, Y.; Ohnuki, T.; Ishii, M.M.; Arai, M.; Takatsu, T.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359s. III. Deaminocaprolactam derivatives of capuramycin: A-500359 E, F, H, M-1 and M-2. J. Antibiot., 2003, 56, 259-67.
157. Muramatsu, Y.; Ohnuki, T.; Ishii, M.M.; Kizuka, M.; Enokita, R.; Miyakoshi, S.; Takatsu, T.; Inukai, M. A-503083 A, B, E and F, novel inhibitors of bacterial translocase I, produced by streptomyces sp. SANK 62799. J. Antibiot., 2004, 57, 639-46.
158. Igarashi, M.; Takahashi, Y.; Shitara, T.; Nakamura, H.; Naganawa, H.; Miyake, T.; Akamatsu, Y. Caprazamycins, novel liponucleoside antibiotics, from streptomyces sp. II. Structure elucidation of caprazamycins. J. Antibiot., 2005, 58, 327-37.
159. Hotoda, H.; Daigo, M.; Furukawa, M.; Murayama, K.; Hasegawa, C.A.; Kaneko, M.; Muramatsu, Y.; Ishii, M.M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.; Kakuta, M.; Abe, T.; Fukuoka, T.; Utsui, Y.; Ohya, S. Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds. Bioorg. Med. Chem. Lett., 2003, 13, 2833-36.
160. Hotoda, H.; Furukawa, M.; Daigo, M.; Murayama, K.; Kaneko, M.; Muramatsu, Y.; Ishii, M.M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.; Kakuta, M.; Abe, T.; Harasaki, T.; Fukuoka, T.; Utsui, Y.; Ohya, S. Bioorg. Med. Chem. Lett., 2003, 13, 2829-32.
161. Ibba, M.; Söll, D. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem., 2000, 69, 617-50.
162. Maus, C.E.; Plikaytis, B.B.; Shinnick, T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 3192-97.
163. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S.G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 1447-54.
164. Swaney, S.M.; Aoki, H.; Ganoza, M.C.; Shinabarger, D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother., 1998, 42, 3251-55.
165. Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs, 1999, 8, 1195-202.
166. Aoki, H.; Ke, L.; Poppe, S.M.; Poel, T.; Weaver, E.A.; Gadwood, R.C.; Thomas, R.C.; Shinabarger, D.L.; Ganoza, M.C. Oxazolidinone Antibiotics Target the P Site on Escherichia coli Ribosomes. Antimicrob. Agents Chemother., 2002, 46, 1080-85.
167. Colca, J.R.; McDonald, W.G.; Waldon, D.J.; Thomasco, L.M.; Gadwood, R.C.; Lund, E.T.; Cavey, G.S.; Mathews, W.R.; Adams, L.D.; Cecil, E.T.; Pearson, J.D.; Bock, J.H.; Mott, J.E.; Shinabarger, D.L.; Xiong, L.; Mankin, A.S. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem., 2003, 278, 21972-79.
168. Franceschi, F.; Duffy, E.M. Structure-based drug design meets the ribosome. Biochem. Pharmacol., 2006, 71, 1016-25.
169. Barbachyn, M.R.; Ford, C.W. Oxazolidinone structure-activity relationships leading to linezolid. Angew. Chem., Int. Ed., 2003, 42, 2010-23.
170. Hutchinson, D.K. Oxazolidinone antibacterial agents: a critical review. Curr. Top. Med. Chem., 2003, 3, 1021-42.
171. Hutchinson, D.K. Recent advances in oxazolidinone antibacterial agent research. Expert Opin. Ther. Pat., 2004, 14, 1309-28.
172. Gravestock, M.B. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr. Opin. Drug Discov. Devel., 2005, 8, 469-77.
173. Quesnelle, C.A.; Gill, P.; Roy, S.; Dodier, M.; Marinier, A.; Martel, A.; Snyder, L.B.; D'Andrea, S.V.; Bronson, J.J.; Frosco, M.; Beaulieu, D.; Warr, G.A.; Denbleyker, K.L.; Stickle, T.M.; Yang, H.; Chaniewski, S.E.; Ferraro, C.A.; Taylor, D.; Russell, J.W.; Santone, K.S.; Clarke, J.; Drain, R.L.; Knipe, J.O.; Mosure, K.; Barrett, J.F. Biaryl isoxazolinone antibacterial agents. Bioorg. Med. Chem. Lett., 2005, 15, 2728-33.
174. Ashtekar, D.R.; Costa-Periera, R.; Shrinivasan, T.; Iyyer, R.; Vishvanathan, N.; Rittel, W. Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis., 1991, 14, 465-71.
175. Brumfitt, W.; Hamilton-Miller, J.M.T. Antibacterial oxazolidinones: In vitro activity of a new analogue, E3709. Diagn. Microbiol. Infect. Dis., 1992, 15, 621-25.
176. Barbachyn, M.R.; Hutchinson, D.K.; Brickner, S.J.; Cynamon, M.H.; Kilburn, J.O.; Klemens, S.P.; Glickman, S.E.; Grega, K.C.; Hendges, S.K.; Toops, D.S.; Ford, C.W.; Zurenko, G.E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem., 1996, 39, 680-85.
177. Terreni, M.; Villani, P. New anti-Mycobacterium agents: recent advances in patent literature. Expert Opin. Ther. Pat., 2001, 11, 261-68.
178. Sbardella, G.; Mai, A.; Artico, M.; Loddo, R.; Setzu, M.G.; La Colla, P. Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorg. Med. Chem. Lett., 2004, 14, 1537-41.
179. Dixit, P.D.; Patil, V.J.; Nair, P.S.; Jain, S.; Sinha, N.; Arora, S.K. Synthesis of 1-3-(4-benzotriazol-1/ 2-yl-3-fluoro-phenyl)-2-oxooxazolidin-5-ylmethyl-3-substituted-thiourea derivatives as antituberculosis agents. Eur. J. Med. Chem., 2006, 41, 423-28.
180. Vera-Cabrera, L.; Castro-Garza, J.; Rendon, A.; Ocampo-Candiani, J.; Welsh, O.; Choi, S. H.; Blackwood, K.; Molina-Torres, C. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob. Agents Chemother., 2005, 49, 4351-53.
181. Das, B.; Rudra, S.; Yadav, A.; Ray, A.; Rao, A.V.;Srinivas, A.S.; Soni, A.; Saini, S.; Shukla, S.; Pandya, M.; Bhateja, P.; Malhotra, S.; Mathur, T.; Arora, S.K.; Rattan, A.; Mehta, A. Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid. Bioorg. Med. Chem. Lett., 2005, 15, 4261-67.
182. Ednie, L.M.; Rattan, A.; Jacobs, M.R.; Appelbaum, P.C. Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents Chemother., 2003, 47, 1143-47.
183. Bush, K.; Macielag, M.J.; Weidner-Wells, M.A. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr. Opin. Microbiol., 2004, 7, 466-76.
184. Sood, R.; Rao, M.; Singhal, S.; Rattan, A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int. J. Antimicrob. Agents, 2005, 25, 464-68.
185. Rao, M.; Sood, R.; Malhotra, S.; Fatma, T.; Upadhyay, D.J.; Rattan, A. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex. J. Chemother., 2006, 18, 144-50.
186. Pucci, M.J.; Bronson, J.J.; Barrett, J.F.; DenBleyker, K.L.; Discotto, L.F.; Fung-Tomc, J.C.; Ueda, Y. Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob. Agents Chemother., 2004, 48, 3697-701.
187. Brooks, G.; Burgess, W.; Colthurst, D.; Hinks, J.D.; Hunt, E.; Pearson, M.J.; Shea, B.; Takle, A.K.; Wilson, J.M.; Woodnutt, G. Pleuromutilins. Part 1: The identification of novel mutilin 14-carbamates. Bioorg. Med. Chem., 2001, 9, 1221-31.
188. Springer, D.M.; Sorenson, M.; Huang, S.; Connolly, T.P.; Bronson, J.J.; Matson, J.A.; Hanson, R.L.; Brzozowski, D.B.; LaPorte, T.L.; Patel, R.N. Synthesis and activity of a C-8 keto pleuromutilin derivative. Bioorg. Med. Chem. Lett., 2003, 13, 1751-53.
189. Bacqué, E.; Pautrat, F.; Zard, S.Z. A flexible strategy for the divergent modification of pleuromutilin. Chem. Commun., 2002, 2312-13.
190. Springer, D.M.; Goodrich, J.T.; Huang, S. A novel ring expansion of the pleuromutilin skeleton. Tetrahedron Lett. 2002, 43, 4857-60.
191. Dean,D.K.; Naylor, A.; Takle, A.K. Pleuromutilin 'beta'-ketoesters. Patent WO 2001014310; see Chem. Abstr. 2001, 134, 193590.
192. Dean, D.K.; Naylor, A.; Takle, A.K. Pleuromutilin derivatives with antimicrobial activity. Patent WO 2002038528; see Chem. Abstr. 2002, 136, 386275.
193. Poulsen, S.M.; Karlsson, M.; Johansson, L.B.; Vester, B. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol., 2001, 41, 1091-99.
194. Long, K.S.; Hansen, L.H.; Jakobsen, L.; Vester, B. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother., 2006, 50, 1458-62.
195. Schlüenzen, F.; Pyetan, E.; Fucini, P.; Yonath, A.; Harms, J.M. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol., 2004, 54, 1287-94.
196. Ascher, G.; Stauffer, F.; Berner, H.; Mang, R. Tuberculosis treatment using pleuromutilin derivatives. Patent WO 2003082260; see Chem. Abstr., 2003, 139, 302016.
197. De Souza, M.V.N. Promising drugs against tuberculosis. Recent Pat. Anti-Infective Drug Discov., 2006, 1, 33-44.
198. Potkar, C.; Gogtav, N.; Gokhale, P.; Kshirsagar, N.A.; Ajay, S.; Cooverji, N.D.; Bruzzese, T. Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. Chemotherapy, 1999, 45, 147-53.
199. Hulikal, V.; Rao, K.R. Indole derivatives for the treatment of tuberculosis, Patent WO 2006 067392; see Chem. Abstr., 2006, 145, 103547.
200. Ji, B.; Lounis, N.; Maslo, C.; Truffot-Pernot, C.; Bonnafous, P.; Grosset, J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1998, 42, 2066-69.
201. Miyazaki, E.; Miyazaki, M.; Chen, J.M.; Chaisson, R.E.; Bishai, W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother., 1999, 43, 85-89.
202. Ruiz-Serrano, M.J.; Alcala, L.; Martinez, L.; Diaz, M.; Martin, M.; Gonzalez-Abad, M.J.; Bouza, E. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents Chemother., 2000, 44, 2567-68.
203. Zhao, B.Y., Pine, R.; Domagala, J.; Drlica, K. Fluoroquinolone action against clinical isolates of mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob. Agents Chemother., 1999, 43, 661-66.
204. Biedenbach, D.J.; Sutton, L.D.; Jones, R.N. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob. Agents Chemother., 1995, 39, 2325-30.
205. Nakashima, M.; Uematsu, T.; Kosuge, K.; Umemura, K.; Hakusui, H.; Tanaka, M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother., 1995, 39, 170-74.
206. Milatovic, D.; Schmitz, F.J.; Brisse, S.; Verhoef, J.; Fluit, A.C. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob. Agents Chemother., 2000, 44, 1102-04.
207. Onodera, Y.; Uchida, Y.; Tanaka, M.; Sato, K. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumonia. J. Antimicrob. Chemother., 1999, 44, 533-36.
208. Oleksijew, A.; Meulbroek, J.; Ewing, P.; Jarvis, K.; Mitten, M.; Paige, L.; Tovcimak, A.; Nukkula, M.; Chu, D.; Alder, J.D. In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother., 1998, 42, 2674-77.
209. Doi, N.; Disratthakit, A. 46th Annual interscience conference on antimicrobial agents and chemotherapy (ICAAC), Poster No. F-0491 and F-0492, San Francisco, 2006.
210. Takahata, M.; Mitsuyama, J.; Yamashiro, Y.; Yonezawa, M.; Araki, H.; Todo, Y.; Minami, S.; Watanabe, Y.; Narita, H. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-f(6)- quinolone. Antimicrob. Agents Chemother., 1999, 43, 1077-84.
211. Roychoudhury, S.; Ledoussal, B. Non-fluorinated quinolones (nfqs): new antibacterials with unique properties against quinoloneresistant gram-positive pathogens. Curr. Drug Targets Infect. Disord., 2002, 2, 51-65.
212. Munier-Lehmann, H.; Chaffotte, A.; Pochet, S.; Labesse, G. Thymidylate kinase of Mycobacterium tuberculosis: a chimera sharing properties common to eukaryotic and bacterial enzymes. Protein Sci., 2001, 10, 1195-05.
213. Pochet, S.; Dugue, L.; Douguet, D.; Labesse, G.; Munier-Lehmann, H. Nucleoside analogues as inhibitors of thymidylate kinases: possible therapeutic applications. ChemBioChem, 2002, 3, 108-10.
214. Vanheusden, V.; Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Synthesis and evaluation of thymidine-5′-Omonophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett., 2002, 12, 2695-98.
215. Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Dugue, L.; Heyerick, A.; Keukeleire, D.D.; Pochet, S.; Busson, R.; Herdewijn, P.; Calenbergh, S.V. 3'-C-branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem., 2003, 46, 3811-21.
216. Munier-Lehmann, H.; Pochet, S.; Dugue, L.; Dutruel, O.; Labesse, G.; Douget, D. Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. Nucleosides Nucleotides Nucleic Acids, 2003, 22, 801-04.
217. Haouz, A.; Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Herdewijn, P.; Van Calenbergh, S.; Delarue, M. Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase. new insights into the phosphoryl transfer mechanism. J. Biol. Chem., 2003, 278, 4963-71.
218. Vanheusden, V.; Van Rompaey, P.; Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Thymidine and thymidine-5′-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett., 2003, 13, 3045-48.
219. Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Busson, R.; Rozenski, J.; Herdewijn, P.; van Calenbergh, S. Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem., 2004, 47, 6187-94.
220. Douguet, D.; Munier-Lehmann, H.; Labesse, G.; Pochet, S. LEA3D: A computer-aided ligand design for structure-based drug design. J. Med. Chem., 2005, 48, 2457-68.
221. Van Daele, I.; Munier-Lehmann, H.; Hendrickx, P.M.; Marchal, G.; Chavarot, P.; Froeyen, M.; Qing, L.; Martins, J.C.; Van Calenbergh, S. Synthesis and biological evaluation of bicyclic nucleosides as inhibitors of M. tuberculosis thymidylate kinase. ChemMed-Chem., 2006, 1, 1081-90.
222. Munier-Lehmann, H.; Douguet, D.; Labesse, G.; Pochet, S. Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents. Patent WO 2006 048336; see Chem. Abstr. 2006, 144, 468192.
223. Johar, M.; Manning, T.; Kunimoto, D.Y.; Kumar, R. Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. Bioorg. Med. Chem., 2005, 13, 6663-71.
224. Rai, D.; Johar, M.; Manning, T.; Agrawal, B.; Kunimoto, D.Y.; Kumar, R. Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. J. Med. Chem., 2005, 48, 7012-07.
225. Chen, C.K.; Barrow, E.W.; Allan, P.W.; Bansal, N.; Maddry, J.A.; Suling, W.J.; Barrow, W.W.; Parker, W. B. The metabolism of 2-methyladenosine in Mycobacterium smegmatis. Microbiology, 2002, 148, 289-95.
226. Long, M.C.; Allan, P.W.; Luo, M.Z.; Liu, M.C.; Sartorelli, A.C.; Parker, W.B. Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth. J. Antimicrob. Chemother., 2007, 59, 118-21.
227. Long, M.C.; Parker, W.B. Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis: I. Modifications to the adenine moiety. Biochem. Pharmacol., 2006, 14, 1671-82.
228. Tendler, S.J.B.; Threadgill, M.D.; Tisdale, M. Activities of serine hydroxymethyltransferase in murine tissues and tumours. J. Cancer Lett., 1987, 36, 65-69.
229. Zanetti, K.A.; Stover, P.J. Pyridoxal phosphate inhibits dynamic subunit interchange among serine hydroxymethyltransferase tetramers. J. Biol. Chem., 2003, 278, 10142-49.
230. Li, R.; Sirawaraporn, R.; Chitnumsub, P.; Sirawaraporn, W.; Wooden, J.; Athappilly, F.; Turley, S.; Hol, W.G. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol., 2000, 295, 307-23.
231. Then, R.L. Antimicrobial dihydrofolate reductase inhibitors - achievements and future options: review. J. Chemother., 2004, 16, 3-12.
232. White, E.L.; Ross, L.R.; Cunningham, A.; Escuyer, V. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase. FEMS Microbiol. Lett., 2004, 232, 101-05.
233. El-Hamamsy, M.H.R.I.; Smith, A.W.; Thompson, A.S.; Threadgill, M.D. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg. Med. Chem., 2007, 15, 4552-76.
234. Suling, W.J.; Reynolds, R.C.; Barrow, E.W.; Wilson, L.N.; Piper, J.R.; Barrow, W.W. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother., 1998, 42, 811-15.
235. Suling, W.J.; Seitz, L.E.; Pathak, V.; Westbrook, L.; Barrow, E.W.; Zywno-Van-Ginkel, S.; Reynolds, R. C.; Piper, J.R.; Barrow, W.W. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase. Antimicrob. Agents Chemother., 2000, 44, 2784-93.
236. Gerum, A.B.; Ulmer, J.E.; Jacobus, D.P.; Jensen, N.P.; Sherman, D.R.; Sibley, C.H. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob. Agents Chemother., 2002, 46, 3362-69.
237. De Voss, J.J.; Rutter, K.; Schroeder, B.G.; Barry, C.E., 3rd. Iron acquisition and metabolism by mycobacteria. J. Bacteriol., 1999, 181, 4443-51.
238. Guo, H.; Naser, S.A.; Ghobrial, G.; Phanstiel, O. IV. Synthesis and biological evaluation of new citrate-based siderophores as potential probes for the mechanism of iron uptake in mycobacteria. J. Med. Chem., 2002, 45, 2056-63.
239. Poreddy, A.R.; Schall, O.F.; Marshall, G.R.; Ratledge, C.; Slomczynska, U. Solid-phase synthesis of methyl carboxymycobactin T 7 and analogues as potential antimycobacterial agents. Bioorg. Med. Chem. Lett., 2003, 13, 2553-56.
240. Ratledge, C. Iron enhances the susceptibility of pathogenic mycobacteria to isoniazid, an antitubercular drug. Tuberculosis, 2004, 84, 110-30.
241. Ferreras, J.A.; Ryu, J.S.; Di Lello, F.; Tan, D.S.; Quadri, L.E. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat. Chem. Biol., 2005, 1, 29-34.
242. Somu, R.V.; Boshoff, H.; Qiao, C.; Bennett, E.M.; Barry, C.E., 3rd.; Aldrich, C.C. Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J. Med. Chem., 2006, 49, 31-34.
243. Harrison, A.J.; Yu, M.; Gardenborg, T.; Middleditch, M.; Ramsay, R.J.; Baker, E.N.; Lott, J.S. The Structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase. J. Bacteriol., 2006, 188, 6081-91.
244. Guillemont, J.E.G.; van Gestel, J.F.E.; Venet, M.G.; Poignet, H.J.J.; Decrane, L.F.B.; Vernier, D.F.J. Quinoline derivatives and their use as mycobacterial inhibitors. Patent WO 2004 11,436; see Chem. Abstr. 2004, 140, 163715k.
245. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H.W.; Neefs, J.M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-27.
246. Guillemont, J.E.G.; Pasquier, E.T.J.; Lancois, D.F.A. Quinoline derivatives and use thereof as mycobacterial inhibitors. Patent WO 2005 70,430; see Chem. Abstr. 2005, 143, 193916f.
247. Guillemont, J. E. G.; Pasquier, E.T.J. Substituted quinolines and their use as mycobacterial inhibitors Patent WO 2005 70,924; see Chem. Abstr. 2005, 143, 194012v.
248. Guillemont, J. E. G.; Pasquier, E.T.J.; Lancois, D. F. A. Quinoline derivatives for use as mycobacterial inhibitors, Patent WO 2005 75,428; see Chem. Abstr. 2005, 143, 229731h.
249. Gaurrand, S.; Desjardins, S.; Meyer, C.; Bonnet, P.; Argoullon, J.M.; Oulyadi, H.; Guillemont, Conformational analysis of R207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. J. Chem. Biol. Drug Des., 2006, 68, 77-84.
250. Ruiz, A.; Papathanassiu, A. Compositions and methods for the treatment of mycobacterial infections Patent U.S. 2004 87,489, see Chem. Abstr. 2004, 140, 368646k.
251. Bermudez, L.E.; Kolonoski, P.; Wu, M.; Aralar, P.A.; Inderlied, C.B.; Young, L.S. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob. Agents Chemother., 1999, 43, 1870-74.
252. Nannini, E.C.; Keating, M.; Binstock, P.; Samonis, G.; Kontoyiannis, D.P. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J. Infect., 2002, 44, 201-03.
253. Danelishvili, L.; Wu, M.; Young, L.S.; Bermudez, L.E. Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria. Antimicrob. Agents Chemother., 2005, 49, 3707-14.
254. Sun, Z.; Zhang, Y. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuberc. Lung Dis., 1999, 79, 319-20.
255. Guardiola-Diaz, H.M.; Foster, L.A.; Mushrush, D.; Vaz, A.D. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem. Pharmacol., 2001, 61, 1463-70.
256. McLean, K.J.; Marshall, K.R.; Richmond, A.; Hunter, I.S.; Fowler, K.; Kieser, T.; Gurcha, S.S.; Besra, G. S.; Munro, A.W. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology, 2002, 148, 2937-49.
257. Ahmad, Z.; Sharma, S.; Khuller, G.K.; Singh, P.; Faujdar, J.; Katoch, V.M. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2006, 28, 543-44.
258. Matsuura, K.; Yoshioka, S.; Tosha, T.; Hori, H.; Ishimori, K.; Kitagawa, T.; Morishima, I.; Kagawa, N.; Waterman, M.R. Structural diversities of active site in clinical azole-bound forms between sterol 14 -demethylases (CYP51s) from human and Mycobacterium tuberculosis. J. Biol. Chem., 2005, 280, 9088-96.
259. Seward, H.E.; Roujeinikova, A.; McLean, K.J.; Munro, A.W.; Leys, D. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-p450 binding mode. J. Biol. Chem., 2006, 281, 39437-43.
260. Erickson, H. P. FtsZ, a prokaryotic homolog of tubulin? Cell, 1995, 80, 367-70.
261. Bramhill, D. Bacterial cell division. Annu. Rev. Cell Dev. Biol., 1997, 13, 395-424.
262. White, E.L.; Suling, W.J.; Ross, L.J.; Seitz, L.E.; Reynolds, R.C. 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J. Antimicrob. Chemother., 2002, 50, 111-14.
263. Reynolds, R.C.; Srivastava, S.; Ross, L.J.; Suling, W.J.; White, E.L. A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ. Bioorg. Med. Chem. Lett., 2004, 14, 3161-04.
264. Lappchen, T.; Hartog, A.F.; Pinas, V.A.; Koomen, G.J.; den Blaauwen, T. GTP analogue inhibits polymerization and GTPase activity of the bacterial protein FtsZ without affecting its eukaryotic homologue tubulin. Biochemistry, 2005, 44, 7879-84.
265. Huang, C.C.; Smith, C.V.; Glickman, M.S.; Jacobs, W.R., Jr.; Sacchettini, J.C. Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J. Biol. Chem., 2002, 277, 11559-69.
266. Wang, J.; Galgoci, A.; Kodali, S.; Herath, K. B.; Jayasuriya, H.; Dorso, K.; Vicente, F.; Gonzalez, A.; Cully, D.; Bramhill, D.; Singh, S. Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem., 2003, 278, 44424-28.
267. Sutherland, A.G.; Alvarez, J.; Ding, W.; Foreman, K.W.; Kenny, C.H.; Labthavikul, P.; Mosyak, L.; Petersen, P.J.; Rush, T.S.; Ruzin, A.; Tsao, D.H.H.; Wheless, K.L. Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. Org. Biomol. Chem., 2003, 1, 4138-40.
268. Jennings, L.D.; Foreman, K.W.; Rush, T.S.; Tsao, D.H.H.; Mosyak, L.; Li, Y.; Sukhdeo, M.N.; Ding, W.; Dushin, E.G.; Kenny, C.H.; Moghazeh, S.L.; Petersen, P.J.; Ruzin, A.V.; Tuckman, M.; Sutherland, A.G. Design and synthesis of indolo[2,3-aquinolizin-7-one inhibitors of the ZipA-FtsZ interaction. Bioorg. Med. Chem. Lett., 2004, 14, 1427-31.
269. Jennings, L.D.; Foreman, K.W.; Rush, T.S. 3rd.; Tsao, D.H.; Mosyak, L.; Kincaid, S.L.; Sukhdeo, M.N.; Sutherland, A.G.; Ding, W.; Kenny, C.H.; Sabus, C.L.; Liu, H.; Dushin, E.G.; Moghazeh, S.L.; Labthavikul, P.; Petersen, P.J.; Tuckman, M.; Haney, S.A.; Ruzin, A.V. Combinatorial synthesis of substituted 3-(2-indolyl) piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg. Med. Chem., 2004, 12, 5115-31.
270. Margalit, D.N.; Romberg, L.; Mets, R.B.; Hebert, A.M.; Mitchison, T.J.; Kirschner, M.W.; RayChaudhuri, D. Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Sci. USA, 2004, 101, 11821-26.
271. Stokes, N.R.; Sievers, J.; Barker, S.; Bennett, J.M.; Brown, D.R.; Collins, I.; Errington, V.M.; Foulger, D.; Hall, M.; Halsey, R.; Johnson, H.; Rose, V.; Thomaides, H. B.; Haydon, D.J.; Czaplewski, L.G.; Errington, J. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem., 2005, 280, 39709-15.
272. Ito, H.; Ura, A.; Oyamada, Y.; Tanitame, A.; Yoshida, H.; Yamada, S.; Wachi, M.; Yamagishi, J. A 4-aminofurazan derivative-A189 - inhibits assembly of bacterial cell division protein FtsZ in vitro and in vivo. J. Microbiol. Immunol., 2006, 50, 759-64.
273. Temple, C.G. Synthesis and evaluation of 1-deaza-7,8-dihydropteridines and ring analogs, In H.-C. Curius, Chemistry and biology of pteridines. Ghisla, S.; Blau N. (Eds.), Walter de Gruyter, Berlin, Germany, 1990, pp.1009-14.
274. Temple, C.G.; Wheeler, G.P.; Elliott, R.D.; Rose, J.D.; Comber, R.N.; Montgomery, J.A. 1,2-Dihydropyrido3,4-bpyrazines: structure- activity relationships. J. Med. Chem., 1983, 26, 91-95.
275. Huang, Q.; Kirikae, F.; Kirikae, T.; Pepe, A.; Amin, A.; Respicio, L.; Slayden, R.A.; Tonge, P.J.; Ojima, I. Targeting FtsZ for antituberculosis drug discovery: non-cytotoxic taxanes as novel antituberculosis agents. J. Med. Chem., 2006, 49, 463-66.
276. Nair, P.A.; Carlisle-Moore, L.; Kisker, C.; Slayden, R.; Kirikae, T.; Ojima, I.; Tonge, P. J. In 226th ACS National Meeting, 2003; Biol-123.
277. Yadav, N., McDevitt, R.E.; Benard, S.; Falco, S.C. Single amino acid substitutions in the enzyme acetolactate synthase confer resistance to the herbicide sulfometuron methyl. Proc. Natl. Acad. Sci. USA, 1986, 83, 4418-22.
278. Grandoni, J.A.; Marta, P.T.; Schloss, J.V. Inhibitors of branchedchain amino acid biosynthesis as potential antituberculosis agents. J. Antimicrob. Chemother., 1998, 42, 475-82.
279. Grandoni, J. Method for treating Mycobacterium tuberculosis. Patent U.S. 5998420, see Chem. Abstr. 1999, 127, 326510.
280. Choi, K. J.; Yu, Y.G.; Hahn, H. G.; Choi, J.D.; Yoon, M.Y. Characterization of acetohydroxyacid synthase from Mycobacterium tuberculosis and the identification of its new inhibitor from the screening of a chemical library. FEBS Lett., 2005, 579, 4903-10.
281. Koul, A.; Herget, T.; Kleb, B.; Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nat. Rev. Microbiol., 2004, 2, 189-202.
282. Matyk, J.; Waisser, K.; Drazkova, K.; Kunes, J.; Klimesova, V.; Palat, K., Jr.; Kaustova, J. Heterocyclic isosters of antimycobacterial salicylanilides. Farmaco Ed. Sci., 2005, 60, 399-408.
283. Waisser, K.; Matyk, J.; Divisova, H.; Husakova, P.; Kunes, J.; Klimesova, V.; Kaustova, J.; Mollmann, U.; Dahse, H.M.; Miko, M. The oriented development of antituberculotics: salicylanilides. Arch. Pharm., 2006, 339, 616-20.
284. Rickman, L.; Saldanha, J. W.; Hunt, D. M.; Hoar, N.; Colston, M. J.; Millar, J. B.; Buxton, R. S. A two-component signal transduction system with a PAS domain-containing sensor is required for virulence of Mycobacterium tuberculosis in mice. Biochem. Biophys. Res. Commun., 2004, 314, 259-67.
285. Av-Gay, Y.; Everett, M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol., 2000, 8, 238-44.
286. Greenstein, A.E.; Grundner, C.; Echols, N.; Gay, L.M.; Lombana, T.N.; Miecskowski, C.A.; Pullen, K.E.; Sung, P.; Alber, T. Structure/ function studies of Ser/Thr and Tyr protein phosphorylation in Mycobacterium tuberculosis. J. Mol. Microbiol. Biotechnol., 2005, 9, 167-81.
287. Peirs, P.; De Wit, L.; Braibant, M.; Huygen, K.; Content, J. A serine/ threonine protein kinase from Mycobacterium tuberculosis. J. Eur. J. Biochem., 1997, 244, 604-12.
288. Drews, S.J.; Hung, F.; Av-Gay, Y. A protein kinase inhibitor as an antimycobacterial agent. FEMS Microbiol. Lett., 2001, 205, 369-74.
289. Davies, J. E.; Waters, B. Antibacterial agents and methods of identification. Patent WO 2002 022138; see Chem. Abstr. 2002, 136, 259921.
290. Walburger, A.; Koul, A.; Ferrari, G.; Nguyen, L.; Prescianotto-Baschong, C.; Huygen, K.; Klebl, B.; Thompson, C.; Bacher, G.; Pieters, J. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science, 2004, 304, 1800-04.
291. Koul, A.; Klebl, B.; Mueller, G.; Missio, A.; Schwab, W.; Hafenbradl, D.; Neumann, L.; Sommer, M.-N.; Mueller, S.; Hoppe, E.; Freisleben, A.; Backes, A.; Hartung, C.; Felber, B.; Zech, B.; Engkvist, O.; Keri, G.; Oerfi, L.; Banhegyi, P.; Greff, Z.; Horvath, Z.; Varga, Z.; Marko, P.; Pato, J.; Szabadkai, I.; Szekelyhidi, Z.; Waczek, F. Heterobicyclic compounds as pharmaceutically active agents. Patent WO 2005 023818; see Chem. Abstr. 2005, 142, 316820.
292. Pato, J.; Keri, G.; Orfi, L.; Waczeck, F.; Horvath, Z.; Banhegyi, P.; Szabadkai, I.; Marosfaldi, J.; Hegymegi-Barkonyi, B.; Szekelyhidi, Z.; Greff, Z.; Choidas, A.; Bacher, G.; Missio, A.; Koul, A. Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor. Patent U.S. 2004 171603; see Chem. Abstr. 2004, 141, 236625p.
293. DiSanto, R.; Costi, R.; Artico, M.; Massa, S.; Lampis, G.; Deidda, D.; Pompei, R. Pyrrolnitrin and related pyrroles endowed with antibacterial activities against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 1998, 8, 2931-36.
294. McKinney, J.D.; Höner, Zu, Bentrup, K.; Munoz-Elías, E.J., Miczak, A.; Chen B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R., Jr.; Russel, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-38.
295. Clements, J.M.; Beckett, R.P.; Brown, A.; Catlin, G.; Lobell, M.; Palan, S.; Thomas, W.; Whittaker, M.; Wood, S.; Salama, S.; Baker, P.J.; Rodgers, H.F.; Barynin, V.; Rice, D.W.; Hunter, M.G. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother., 2001, 45, 563-70.
296. Cynamon, M.H.; Alvirez-Freites, E.J.; Yeo, A.E. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2004, 53, 403-05.
297. Teo, J.W.; Thayalan, P.; Beer, D.; Yap, A.S.;Nanjundappa, M.; Ngew, X.; Duraiswamy, J.; Liung, S.; Dartois, V.; Schreiber, M.; Hasan, S.; Cynamon, M.; Ryder, N.S.; Yang, X.; Weidmann, B.; Bracken, K.; Dick, T.; Mukherjee, K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother., 2006, 50, 3665-73.
298. Giglione, C.; Pierre, M.; Meinnel, T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol., 2000, 36, 1197-205.
299. Pershin, G.N.; Nesvadba, V.V. A study of monoamino oxidase activity in mycobacteria. Bull. Exp. Biol. Med., 1963, 81-83.
300. Velezheva, V.S.; Brennan, P.J.; Marshakov, V.Y.; Gusev, D.V.; Lisichkina, I.N.; Pergudov, A.S.; Tchernousova, L.N.; Smirnova, T.G.; Andreevskaya, S.N.; Medvedev, A.E. Novel pyridazino[4,3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase. J. Med. Chem., 2004, 47, 3455-61.
301. Amaral, L.; Kristiansen, J.E.; Viveiros, M.; Atouguia, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother., 2001, 47, 505-11.
302. Salih, F.A.; Kaushik, N.K.; Sharma, P.; Choudary G.V.; Murthy, P.S.; Venkitasubramanian, T.A. Calmodulin-like activity in mycobacteria. Indian J. Biochem. Biophys., 1991, 28, 491-95.
303. Ordway, D.; Viveiros, M.; Leandro, C.; Bettencourt, R; Almeida, J.; Martins, M.; Kristiansen, J.E.; Molnar, J.; Amaral L.J. Clinical concentrations of thioridazine kill intracellular multidrug-resistant mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 917-22.
304. Amaral, L.; Kristiansen, J.E.; Abebe, L.S.; Millett, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother., 1996, 38, 1049-53.
305. Crowle, A.J.; Douvas, G.S.; May, M.H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy, 1992, 38, 410-19.
306. Bettencourt, M.V.; Bosne-David, S.; Amaral, L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2000, 16, 69-71.
307. Weinstein, E.A.; Yano, T.; Li, L.S.; Avarbock, D.; Avarbock, A.; Helm, D.; McColm, A.A.; Duncan, K.; Lonsdale, J.T.; Rubin, H. Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. USA, 2005, 102, 4548-53.
308. Tuck, K.L.; Saldanha, S. A.; Birch, L.M.; Smith, A.G.; Abell, C. The design and synthesis of inhibitors of pantothenate synthetase. Org. Biomol. Chem., 2006, 4, 3598-610.
309. Southworth, K.; Sneed, B.; Ross, L.; Cooley, S.; Sosa, M. I.; Manouvakhova, A.; Rasmussen, L.; White, E. L.; Anathan, A.; Fletcher, T.M., III; Goldman, R.C.; Goulding, C.; Eisenberg, D. Identifying pantothenate synthetase inhibitors of Mycobacterium tuberculosis from a high throughput screen. Presented at the 13th Annual Conference of the Society for Biomolecular Sciences (SBS), Montreal, Canada, 2007.
310. White, E.L.; Southworth, K.; Ross, L.; Cooley, S.; Gill, R.B.; Sosa, M.I.; Manouvakhova, A.; Rasmussen, L.; Goulding, C.; Eisenberg, D.; Fletcher, T.M., 3rd. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J. Biomol. Screen., 2007, 12 , 100-05.
311. Velaparthi, S.; Brunsteiner, M.; Uddin, R.; Wan, B.; Franzblau, S.G.; Petukhov, P.A. 5-tert-Butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo [d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs. J. Med. Chem., 2008, 51, 1999-2002.
312. Aharona, G.F. Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51. Tuberculosis, 2006, 86, 191-97.
313. Robbins, J.B.; Schneerson, R.; Szu, S. C. Hypothesis: how licensed vaccines confer protective immunity. Adv. Exp. Med. Biol. 1996, 397,169-82.
314. Reljic, R.; Clark, S.O.; Williams, A.; Singh, M.; Challacombe, S.; Marsh, P.D.; Ivanyi J. Intranasal IFNγ extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol., 2006; 143, 467-73.
315. Teitelbaum, R.; Glatman-Freedman, A.; Chen, B.; Robbins, JB.; Unanue, E.; Casadevall, A. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl. Acad. Sci. USA, 1998, 95, 15688-93.
316. Williams, A.; Reljic, R.; Naylor, I. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology, 2004, 111, 328-33.
317. Juan, C.P.; Sylvia, C.L.; Viviana, R. Tuberculosis 2007- From basic science to patient care, Brazil, 2007.
318. Uematsu, S.; Akira, S. Innate immunity and tuberculosis. Kekkaku, 2008, 83, 101-09.